1️⃣ GHO and CBC merged the specialist capital stack GHO and CBC signed a merger to create a healthcare-only investment manager with more than US$21bn in AUM, 200 staff and 13 offices.
💡 Why it matters This is a peer-fund signal: specialist healthcare capital is chasing platform scale across Europe, Asia and the US.
☕ Coffee talk At US$21bn, does specialist healthcare capital still bid differently, or just bid bigger?
2️⃣ SERB bought Hansa’s Idefirix geography SERB will acquire EU, UK, Swiss, Nordic and MENA rights to Hansa’s Idefirix for EUR115m, with EUR110m upfront.
💡 Why it matters Hansa gets balance-sheet room before the US PDUFA; SERB gets an approved rare-transplant product with a narrow commercial job.
☕ Coffee talk Is Hansa funding the US launch, or admitting Europe needed a different owner?
3️⃣ Mentari used InMed as a public-market wrapper InMed agreed an all-stock merger with private Mentari, plus a US$290m private placement to fund migraine antibodies into 2028.
💡 Why it matters This is a biotech recap, not a bolt-on: InMed holders are expected to own about 1.5% while Mentari takes the Nasdaq shell.
☕ Coffee talk When the public company keeps 1.5%, are we still calling this a merger?